Stay updated with breaking news from Salvia Bioelectronics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A woman in Nambour, Australia, is the first patient to receive a minimally invasive implantable neuromodulation device for severe migraine and cluster headache in a first-in-human study conducted by Salvia Bioelectronics BV.
/PRNewswire/ -- In a remarkable medical milestone, an Australian patient at Nambour Selangor Private Hospital became the first-ever patient to receive Salvia...
/PRNewswire/ -- The "Neuromodulation Devices Global Market- Forecast To 2029" report has been added to ResearchAndMarkets.com's offering. The neuromodulation...
This report studies the Digital Migraine Treatment Devices Market with many aspects of the industry like the market size, market status, market trends and
This report studies the Semiconductor for Robotics Market with many aspects of the industry like the market size, market status, market trends and forecast, the